Search the site

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with Pneumococcal Conjugate Vaccine

PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses

Cochrane CSOM: A suite of reviews examining the effectiveness of interventions to treat chronic suppurative otitis media (CSOM) globally

Chris Peter Brennan-Jones Richmond PhD MBBS MRCP(UK) FRACP Head, Ear and Hearing Health Head, Vaccine Trials Group chris.brennan-jones@thekids.org.au

Ear Explorers: A ‘real-life research project’ enabling children to view inside their own ears using smartphone video-otoscopy

Chris Brennan-Jones PhD Head, Ear and Hearing Health chris.brennan-jones@thekids.org.au Head, Ear and Hearing Health Professor Chris Brennan-Jones is

Ear Portal: An ENT and Audiology referral portal for improving access to ear health services for children using telehealth

Chris Deborah Peter Tanisha Greta Karina Brennan-Jones Lehmann Richmond Cayley Bernabei Tao PhD AO, MBBS, MSc MBBS MRCP(UK) FRACP BBiomed (Hons) BSc

Koorlungkas yarning: Exploring the impact of OM on early language and communication skills in urban Aboriginal families

Deborah Peter Lehmann Richmond AO, MBBS, MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Head, Vaccine Trials Group Honorary Emeritus Fellow Head,

Clinical Associate Professor Deborah Lehmann

Honorary Emeritus Fellow

Funding boost music to the ears of WA children

A $6 million commitment from Wesfarmers to Telethon will fund vital research to reduce the impact of chronic ear infections and other serious diseases.

Ear and Hearing Health

The Ear and Hearing Health team's vision is all children start primary school with good hearing.

Ear health partnership brings brighter future for Aboriginal kids

A new partnership between The Kids Research Institute Australia, Dr George Sim and St John of God Murdoch Hospital will offer essential surgery at no cost for a group of Aboriginal children suffering severe ear infections.

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.